H.R. 9923 aims to enhance the United States' leadership in biotechnology by recruiting and training experts in the field. These experts would advocate for U.S. biotechnology interests on an international level, ensuring that U.S. priorities are represented in global discussions and negotiations related to biotechnology.
Supporters of H.R. 9923 highlight its potential to strengthen U.S. influence in the rapidly evolving biotechnology sector. They argue that by investing in expert training and international advocacy, the bill could help the U.S. maintain its competitive edge and promote global standards that align with American values and innovations.
Critics of H.R. 9923 express concern that the bill may prioritize U.S. interests at the expense of global cooperation on biotechnology issues. Some argue that it could lead to a unilateral approach that undermines collaborative efforts needed to address global challenges such as health crises and environmental sustainability.
The analysis of H.R. 9923, sponsored by Jim Moylan, reveals no direct industry overlaps between the bill's subject matter and the sponsor's top donor industries. This indicates a low potential for conflicts of interest, as the bill focuses on biotechnology diplomacy while the donor industries do not directly pertain to biotechnology or related sectors. Given that there are no financial ties that could influence the bill's passage or the sponsor's stance, voters can be reassured that the legislation is likely driven by broader national interests rather than specific donor agendas. The absence of overlapping interests suggests that the motivations behind this bill are more aligned with public policy goals than with private financial interests.
Top industries funding James (Jim) Moylan, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
